While effective for some, these approaches often fall short for individuals with underlying metabolic challenges, hormonal imbalances, or age-related barriers
Here, we describe a case of widespread hyperpigmentation of the hard palate mucosa associated with long-term imatinib treatment of a CML patient
Overall, this ITC suggests that there is no statistically significant difference between tirzepatide and semaglutide for the primary outcome of MACE and secondary outcomes of CV and all cause mortality and hospitalization for heart failure
Ultimately, the decision to supplement with glutathione should be based on personal health goals and circumstances
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, but it has not received MHRA marketing authorisation and cannot be legally prescribed in the UK
GLP-1R agonists (e.g., exendin-4 and liraglutide) reduce APP expression and processing in the brains of AD model mice through the activation of GLP-1R, decrease A protein production and plaque aggregation, and thus improve their spatial memory capacity (McClean et al., 2015
